CSPC Pharmaceutical Group Limited has announced an exclusive license agreement with Cipla USA, Inc. for the commercialization of its Irinotecan Liposome Injection in the United States. Under the terms of the agreement, CSPC will receive an upfront payment of $15 million, with potential additional payments of up to $1,050 million based on commercial and regulatory milestones, along with tiered double-digit royalties on annual net sales. The product, developed under CSPC's liposome technology platform, is used in the treatment of multiple solid tumors. This move marks a significant step in CSPC's expansion into the U.S. market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 15, 2025, and is solely responsible for the information contained therein.